Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.39)
# 3,541
Out of 4,981 analysts
76
Total ratings
41.46%
Success rate
-13.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $24.63 | - | 3 | Sep 9, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $200 → $203 | $195.58 | +3.79% | 19 | Aug 8, 2025 | |
| REPL Replimune Group | Upgrades: Overweight | n/a | $5.73 | - | 2 | Jul 30, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $8.19 | - | 11 | Jun 26, 2025 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $32.80 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.52 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $3.14 | - | 1 | Mar 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $7.74 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $1.06 | - | 7 | Jan 24, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $11.52 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $8.59 | +132.83% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.05 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.80 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.83 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.85 | +62.16% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $0.96 | +419.16% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $1.97 | +1,828.93% | 1 | Aug 12, 2022 |
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: n/a
Current: $24.63
Upside: -
Ascendis Pharma
Aug 8, 2025
Maintains: Overweight
Price Target: $200 → $203
Current: $195.58
Upside: +3.79%
Replimune Group
Jul 30, 2025
Upgrades: Overweight
Price Target: n/a
Current: $5.73
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.19
Upside: -
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $32.80
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.52
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.14
Upside: -
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.74
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.06
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.52
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $8.59
Upside: +132.83%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.05
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.80
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.83
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.85
Upside: +62.16%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $0.96
Upside: +419.16%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $1.97
Upside: +1,828.93%